基于DNA测序设计耐多药结核病治疗方案
该研究纳入2015至2019年德国结核参考中心收治的70例耐多药/利福平耐药结核病患者,比较基于二代测序(NGS)的基因组药敏预测与MGIT表型药敏结果的一致性,并评估基因组药敏指导个体化治疗方案设计的可靠性。结果显示基因组与表型药敏总体一致率为86.3%,基因组预测的敏感药物中97.9%被表型确认,基于基因组药敏设计的联合方案中99.0%的药物经表型证实为敏感。
要点
- NGS基因组药敏可可靠指导MDR/RR-TB个体化方案设计。
- 基因组预测敏感的药物97.9%经MGIT表型药敏确认。
- 基因组药敏推断的联合方案中99.0%药物经表型证实敏感。
核心结论
- 基于NGS的基因组药敏检测能够可靠地指导耐多药/利福平耐药结核病有效治疗方案的设计。
研究设计与样本
- 回顾性比较研究,纳入2015年1月1日至2019年4月30日德国一家结核参考中心收治的70例MDR/RR-TB患者。
- 比较NGS基因组药敏预测与MGIT表型药敏结果,并应用标准化治疗算法分别基于基因组或表型药敏设计个体化治疗。
- 对不一致结果使用Sensititre MYCOTBI和UKMYC微量滴定板测定最低抑菌浓度(MIC)进一步评估。
主要发现
- 在70例患者中,基因组与表型药敏共1048对比较的总体一致率为86.3%。
- 76项(7.2%)结果不一致,68项(6.5%)因存在对耐药性意义未知的多态性而无法评估。
- 基因组预测的561项药物敏感结果中,549项(97.9%)经MGIT表型确认。
- 64项假阳性结果中,27项(42.2%)与既往描述的导致低或中等MIC升高的突变相关。
- 基于基因组药敏推断的联合治疗方案中,几乎所有药物(99.0%)经表型药敏证实为敏感。
临床怎么用
- 对于MDR/RR-TB患者,可利用NGS基因组药敏预测结果指导个体化治疗方案的制定。
- 基因组药敏预测敏感的药物具有较高的表型符合率,可作为方案组合的依据。
- 对基因组药敏中意义未知的多态性及假阳性结果,可结合MIC测定进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comprehensive and reliable drug susceptibility testing (DST) is urgently needed to provide adequate treatment regimens for patients with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We determined whether next-generation sequencing (NGS) analysis of Mycobacterium tuberculosis complex isolates and genes implicated in drug resistance can guide the design of effective MDR/RR-TB treatment regimens. METHODS: NGS-based genomic DST predictions of M. tuberculosis complex isolates from MDR/RR-TB patients admitted to a TB reference center in Germany between 1 January 2015 and 30 April 2019 were compared with phenotypic DST results of mycobacteria growth indicator tubes (MGIT). Standardized treatment algorithms were applied to design individualized therapies based on either genomic or phenotypic DST results, and discrepancies were further evaluated by determination of minimal inhibitory drug concentrations (MICs) using Sensititre MYCOTBI and UKMYC microtiter plates. RESULTS: In 70 patients with MDR/RR-TB, agreement among 1048 pairwise comparisons of genomic and phenotypic DST was 86.3%; 76 (7.2%) results were discordant, and 68 (6.5%) could not be evaluated due to the presence of polymorphisms with yet unknown implications for drug resistance. Importantly, 549 of 561 (97.9%) predictions of drug susceptibility were phenotypically confirmed in MGIT, and 27 of 64 (42.2%) false-positive results were linked to previously described mutations mediating a low or moderate MIC increase. Virtually all drugs (99.0%) used in combination therapies that were inferred from genomic DST were confirmed to be susceptible by phenotypic DST. CONCLUSIONS: NGS-based genomic DST can reliably guide the design of effective MDR/RR-TB treatment regimens.
引用
- Grobbel HP, Merker M, Köhler N, et al. Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing. Clin Infect Dis. 2021. PMID: 33900387. doi:10.1093/cid/ciab359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。